Shots:

• The 6mos. P-III (V-MONO) trial assesses the efficacy of twice-yearly Leqvio alone (n=174) vs PBO (n=87) & ezetimibe (n=89) among patient at low or moderate ASCVD risk, not on lipid-lowering therapy. The 1EPs included percent change in LDL-C at D150
• Study reached its 1EPs, significantly lowering LDL-C. These results will be highlighted at future conferences and shared with regulatory bodies, incl the US FDA
• Novartis is advancing Leqvio in the VICTORION-1-PREVENT (V1P) study for high-risk primary prevention that will complete enrollment in H2’24; the ORION-4 & VICTORION-2-PREVENT (V2P) studies for secondary prevention are underway, with results expected in 2026 & 2027, respectively

Ref: Novartis | Image: Novartis 

Related Post:- Novartis Reports Results from the P-IIIb (V-INITIATE) Study of Leqvio for Treating Atherosclerotic Cardiovascular Disease (ASCVD)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com